Whalesbook
India's pharmaceutical sector faces a challenging Q4 FY26. While domestic demand is strong, export headwinds and operational issues are significantly squeezing profit margins. Nuvama Institutional Equities forecasts only 3% EBITDA growth and a 6% drop in net profit, despite a projected 10% revenue increase. Key companies like Cipla are dealing with product recalls and US market erosion, contributing to a higher perception of risk across the industry.
The overall EBITDA margins for the sector are forecast to fall by 1.78 percentage points to 23.1%. This profit compression is mainly due to steeper price drops in the US and specific operational problems.
The Indian Pharma Market (IPM) is a bright spot, predicted to grow 12% annually. This growth is driven by strong sales in cancer drugs (up 33%), heart medications (up 16%), and diabetes treatments (up 16%). Major companies like Sun Pharma, Dr. Reddy's Laboratories, Zydus Lifesciences, and Ajanta Pharma are expected to lead this domestic expansion.
However, the US market remains a major drag. This is primarily because of falling prices on key generics, such as gRevlimid, and broader market competition. This weak export performance is a main reason overall industry profits are declining.
Valuations for these drug companies show investors see different levels of risk. Sun Pharma and Ajanta Pharma trade at higher P/E ratios around 36, suggesting investor optimism tied to their strong domestic business or specialized products. In contrast, Dr. Reddy's and Zydus Lifesciences trade at lower P/E ratios around 18, perhaps due to more balanced global sales or specific US market ties. Cipla, with a P/E ratio around 21, sits in between but faces its own specific issues. This comes as US growth was slower last year, with uncertainty around gRevlimid competition already noted for FY26.
Despite the strong domestic growth narrative, significant risks loom over the sector's profitability. Cipla is especially vulnerable, hit by expected lower gRevlimid sales and, more importantly, a recall of its Lanreotide injection in the US. The recall, prompted by US regulators acting against its manufacturing partner Pharmathen International S.A. over contamination and manufacturing problems, stopped production and led Cipla to lower its own financial forecasts. Relying on a single supplier for key products shows weak links in the supply chain.
The report also highlights broader margin pressure across the industry, caused by falling prices in export markets, less profitable product sales, and higher operating costs. This means strong domestic demand may not fully make up for lower profits from competitive international markets.
Looking ahead, India's pharma sector performance will depend on how well companies handle US market ups and downs and fix operational problems. Domestic demand is expected to keep growing steadily, but competition from generic drugs and supply chain issues will continue to challenge companies' ability to set prices and maintain smooth operations. The different P/E ratios suggest analysts favor companies with strong domestic businesses and those less dependent on the unstable US generics market or single products.